131 |
Mucosal inflammation in allergic rhinitisWilson, Susan Jane January 1994 (has links)
No description available.
|
132 |
Towards the total synthesis of the pseudopterosinsWilden, Jonathan D. January 2000 (has links)
No description available.
|
133 |
Mechanisms of airway cell proliferation and pulmonary inflammation induced by ozone and allergen in Brown-Norway ratsSalmon, Michael January 1999 (has links)
No description available.
|
134 |
Regulation of acute eosinophil mobilisation from the bone marrowPalframan, Roger Thomas January 1999 (has links)
No description available.
|
135 |
Studies on mucin isolation and proteolysisHutton, David Alan January 1991 (has links)
No description available.
|
136 |
Studies on chronic gastrointestinal disease in the horseMurphy, David Matthew January 1997 (has links)
No description available.
|
137 |
The effects of the preferential COX-2 inhibitor, Meloxicam and motion on fracture healingConnolly, Christopher Kevin January 2001 (has links)
No description available.
|
138 |
Mucus glycoproteins in the diverted colorectumEdwards, Cathryn M. January 2000 (has links)
No description available.
|
139 |
The domain organization and function of the integrin β2 subunit (CD18)Tan, Suet Mien January 2000 (has links)
No description available.
|
140 |
Genes, pathways & transcription factors involved in probiotic mediated resolution of gut inflammation in IL10-KO mice, an animal model of inflammatory bowel disease : an integrated gene, protein and bioinformatics approachReiff, Caroline January 2010 (has links)
Genes, pathways & transcription factors involved in probiotic mediated resolution of gut inflammation in IL10-KO mice an animal model of Inflammatory Bowel Disease. An integrated Gene, Protein and Bioinformatics Approach The IL10-KO mouse is a model of human inflammatory bowel disease (IBD), used to study host microbial interactions and potential therapeutics. Affymetrix microarray and proteomics analysis on colon of WT and IL10-KO mice and cecum of IL10-KO and WT mice orally administered with and without probiotic VSL#3 was performed and identified signalling pathways and transcription factors relevant to gut inflammation and anti-inflammatory probiotics. Results were validated by Real-time PCR, immunocytochemistry, proteomics, histopathology and via pathway signature analysis of publicly available microarray data. Changes in metabolically active bacteria in response to VSL#3 were assessed with DGGE. Inflammation in IL10-KO mice was characterised by up-regulation of immune/inflammatory and down-regulation of lipid/xenobiotic metabolism and PPAR signalling. VSL#3 resolved inflammation in the cecum inducing down-regulation of genes in immune/inflammatory pathways, decrease in the number of CCL5 positive T cells and up-regulation of galectin2, known to trigger apoptosis of T cells. VSL#3 induced up-regulation of PPARα/PPAR signalling and lipid/xenobiotic metabolism, antagonistic to NFB signalling and reduced metabolically active bifidobacteria. Analysis of publicly available data showed results were relevant to human IBD, indicated that antigen processing/presentation is up-regulated early on during development of colitis in IL10-KO mice, identified the potential of PPARα/PPAR signalling to induce down-regulation of CCL5, CD3 & antigen processing/presentation, and the potential of the xenobiotic metabolism to induce down-regulation of cytokine-cytokine interaction & mitosis. As VSL#3 treatment of IL10-KO mice induced up-regulation of PPARα/PPAR signalling and xenobiotic metabolism these results provide a possible mechanistic explanation for the VSL#3 induced down-regulation of CCL5, CD3, antigen processing/presentation, cytokine-cytokine interaction and mitosis in the cecum of VSL#3 treated IL10-KO mice.
|
Page generated in 0.0514 seconds